HIGHLIGHTS
- who: Megan L. Sulciner and collaborators from the Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA have published the Article: Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma, in the Journal: (JOURNAL)
- how: This study found that the median disease-free survival was increased in the modified FOLFIRINOX group to 21.6 months as compared to 12.8 months in the gemcitabine group .
SUMMARY
The addition of neoadjuvant chemotherapy has been associated with improved overall survival by downstaging disease and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.